Clinical trials: Skin Toxicity
Colorectal Cancer Metastatic, Skin Toxicity
Panitumumab Skin Toxicity Prevention Trial
Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma.
- Trial name
- PaSTo (NCT03167268)
- Testing
- Lycopene
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Ospedale San Carlo Borromeo
Breast Cancer Female
Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support
ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum care of women with breast cancer…
- Trial name
- ATOPE-PRO (NCT06518200)
- Testing
- Individualised health recommentations, General health recommendations, Individualised physical exercise program
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Universidad de Granada
Breast Cancer, Metastatic Breast Cancer
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
The metabolism of anticancer drugs is influenced by genetic variants that affect their bioavailability and toxicity. In the case of antibody-drug conjugates (ADCs), such as sacituzumab-govitecan (SG), trastuzumab-deruxtecan…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetic Variant
- Trial name
- NCT07582887
- Testing
- Sacituzumab Govitecan, Trastuzumab deruxtecan, Datopotamab Deruxtecan
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Breast Neoplasms
Prediction of Everolimus-induced Interstitial Lung Disease
The investigators will determine which factors are predictive for the development and severity of everolimus-induced interstitial lung disease and will develop a prediction model based on these risk factors.
- Trial name
- PREVENT (NCT01978171)
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Radboud University Medical Center
Metastatic Breast Cancer
Retroprospective Real Life Observatory of Eribulin
The objective of this observatory is to evaluate the effecacy of Eribulin in patients with metastatic breast cancer on a recent prescription period.
- Trial name
- ReProLine (NCT02393287)
- Testing
- Eribulin (ReProLine)
- Where
- 13 sites in France
- Volunteers
- 753 people
- Sponsor
- Institut Cancerologie de l'Ouest
Rheumatoid Arthritis, Osteoarthritis
PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity
To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis
- Trial name
- PRESENT (NCT00576706)
- Testing
- Rebamipide, Misoprostol
- Where
- 10 sites in South Korea
- Volunteers
- 396 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Breast Cancer
Eribulin in HER2 Negative Metastatic BrCa
Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last 30 years, however, overall prognosis remains poor with median survival of 2 to 3 years.
- Trial name
- NCT01827787
- Testing
- Eribulin
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Dana-Farber Cancer Institute
Rare Diseases, Toxic Epidermal Necrolyses
Severe Bullous Drug Eruption and Filgrastim
Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T lymphocytes, specific of drugs, responsible for the…
- Trial name
- GNET (NCT04651439)
- Testing
- Filgrastim
- Where
- 3 sites in France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer
RATIONALE: Identifying genes that increase a person's susceptibility to side effects caused by capecitabine may help doctors plan better treatment.
- Trial name
- NCT00953537
- Testing
- capecitabine, laboratory biomarker analysis, pharmacological study
- Where
- France
- Volunteers
- 303 people
- Sponsor
- Centre Antoine Lacassagne
Toxicity Due to Radiotherapy, Breast Cancer
REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)
The purpose of this study is to determine whether a new technique of radiotherapy for breast cancer (helical tomotherapy) can induce cardiac toxicity that would be detected in the first two years after treatment.
- Conditions
- Toxicity Due to Radiotherapy, Breast Cancer, Lesion; Cardiac
- Trial name
- REBECCA (NCT02079272)
- Testing
- Helical tomotherapy for breast cancer
- Where
- France
- Sponsor
- Sophie JACOB
Cutaneous Melanoma, Cutaneous Melanoma, Stage III
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer.
- Conditions
- Cutaneous Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma by AJCC V7 Stage, Cutaneous Melanoma, Stage IV
- Trial name
- NCT07148245
- Testing
- Blood Sample, Health Related Quality of Life Questionnaires (HRQoL), Medical Chart Review
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Dermatologic Complications
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation…
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00438659
- Testing
- mometasone furoate
- Where
- 189 sites in United States
- Volunteers
- 176 people
- Sponsor
- North Central Cancer Treatment Group
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Skin Toxicity
Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne.
- Trial name
- DERMIA (NCT03448731)
- Testing
- Doxycycline 50Mg Tablet
- Where
- 8 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Breast Cancer, Chemotherapeutic Toxicity
Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients
investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients
- Trial name
- NCT06570811
- Testing
- Coenzyme Q10 200mg twice daily
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Damanhour University
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT04990726
- Testing
- Assessment, Biospecimen Collection, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Cutaneous Squamous Cell Carcinoma (CSCC)
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans, it exhibits a high tumor mutational burden and is more common in immunocompromised patients, which aimed to explore the impact of…
- Trial name
- NGF-GRACE (NCT07064330)
- Testing
- Cemiplimab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Breast Cancer Stage IV
Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with CDKi in patients with HR-positive, HER2-negative advanced breast cancer.
- Trial name
- HeCOG/CDKi (NCT04133207)
- Where
- Greece
- Volunteers
- 340 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer
This trial will compare grade 2 or greater late skin toxicities of concomitant letrozole-radiotherapy and radiotherapy followed by letrozole as adjuvant therapy for postmenopausal women with receptor (estrogen receptor [ER]…
- Trial name
- NCT00208273
- Testing
- Letrozole - Concomitant, Letrozole - Sequential
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Melanoma, Neoplasm Metastasis
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's…
- Trial name
- NCT00001832
- Testing
- gp100:209-217 (210M), Montanide ISA-51, IL-2
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)